Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.

Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA.

Science. 2007 Oct 12;318(5848):287-90. Epub 2007 Sep 13.

2.

Will kinase inhibitors make it as glioblastoma drugs?

Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF.

Curr Top Microbiol Immunol. 2012;355:135-69. doi: 10.1007/82_2011_178. Review.

3.

Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.

Abounader R.

Expert Rev Anticancer Ther. 2009 Feb;9(2):235-45. doi: 10.1586/14737140.9.2.235. Review.

4.

Targeting the AKT pathway in glioblastoma.

McDowell KA, Riggins GJ, Gallia GL.

Curr Pharm Des. 2011;17(23):2411-20. Review.

PMID:
21827416
5.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
6.

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

Porter AC, Vaillancourt RR.

Oncogene. 1998 Sep 17;17(11 Reviews):1343-52. Review.

7.

Should individual PI3 kinase isoforms be targeted in cancer?

Jia S, Roberts TM, Zhao JJ.

Curr Opin Cell Biol. 2009 Apr;21(2):199-208. doi: 10.1016/j.ceb.2008.12.007. Epub 2009 Feb 4. Review.

8.

[Molecular targeted therapy for malignant brain tumors].

Okamura T, Kurisu K.

Nihon Rinsho. 2005 Sep;63 Suppl 9:520-6. Review. Japanese. No abstract available.

PMID:
16201575
9.

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Raizer JJ.

J Neurooncol. 2005 Aug;74(1):77-86. Review.

PMID:
16078112
10.

Incorporating molecular tools into early-stage clinical trials.

Weil RJ.

PLoS Med. 2008 Jan 22;5(1):e21. doi: 10.1371/journal.pmed.0050021. Review. No abstract available.

11.

Combination therapy for malignant glioma based on PTEN status.

Gonzalez J, de Groot J.

Expert Rev Anticancer Ther. 2008 Nov;8(11):1767-79. doi: 10.1586/14737140.8.11.1767. Review.

PMID:
18983237
12.

Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Wallace GC 4th, Dixon-Mah YN, Vandergrift WA 3rd, Ray SK, Haar CP, Mittendorf AM, Patel SJ, Banik NL, Giglio P, Das A.

Metab Brain Dis. 2013 Sep;28(3):355-66. doi: 10.1007/s11011-013-9401-7. Epub 2013 Apr 2. Review.

13.

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.

Mellinghoff IK, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81. Review.

14.

Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

Venkatesan S, Lamfers ML, Dirven CM, Leenstra S.

CNS Oncol. 2016;5(2):77-90. doi: 10.2217/cns-2015-0005. Epub 2016 Mar 17. Review. Erratum in: CNS Oncol. 2016 Jul;5(3):188.

PMID:
26986934
15.

PI3Kinase signaling in glioblastoma.

Lino MM, Merlo A.

J Neurooncol. 2011 Jul;103(3):417-27. doi: 10.1007/s11060-010-0442-z. Epub 2010 Nov 10. Review.

16.

Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.

Abou-Fay├žal C, Hatat AS, Gazzeri S, Eymin B.

Int J Mol Sci. 2017 Feb 11;18(2). pii: E383. doi: 10.3390/ijms18020383. Review.

17.

Current clinical development of PI3K pathway inhibitors in glioblastoma.

Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK.

Neuro Oncol. 2012 Jul;14(7):819-29. doi: 10.1093/neuonc/nos117. Epub 2012 May 22. Review.

18.

G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues.

Cherry AE, Stella N.

Neuroscience. 2014 Oct 10;278:222-36. doi: 10.1016/j.neuroscience.2014.08.015. Epub 2014 Aug 24. Review.

19.

Genetics of glioblastoma: a window into its imaging and histopathologic variability.

Belden CJ, Valdes PA, Ran C, Pastel DA, Harris BT, Fadul CE, Israel MA, Paulsen K, Roberts DW.

Radiographics. 2011 Oct;31(6):1717-40. doi: 10.1148/rg.316115512. Review.

20.

Deregulated signalling networks in human brain tumours.

Grzmil M, Hemmings BA.

Biochim Biophys Acta. 2010 Mar;1804(3):476-83. doi: 10.1016/j.bbapap.2009.10.018. Epub 2009 Oct 29. Review.

PMID:
19879382

Supplemental Content

Support Center